Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients

被引：0
|
作者：
Santos, Allan [1 ]
Santos, Herbert [2 ]
Leal, Joanna [3 ]
Santos, Juliana [2 ,3 ]
Salvino, Marco [4 ]
Lucas, Larissa [3 ]
Santos, Mariane [1 ]
Hungria, Vania T. M. [5 ]
Torres, Alex [6 ]
Crusoe, Edvan de Queiroz [7 ]
机构：
[1] Univ Fed Bahia, Immunol & Cytometry Lab, Salvador, BA, Brazil
[2] Univ Fed Bahia, Salvador, BA, Brazil
[3] Oncol DOr BA Brazil, Salvador, BA, Brazil
[4] Univ Fed Bahia, Bone Marrow Transplantat unit, Salvador, BA, Brazil
[5] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil
[6] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil
[7] Rede Dor Oncol, Salvador, BA, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-244
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [1] Effect of Daratumumab (DARA), Cyclophosphamide (C), T Halidomide (T) and Dexamethasone (D) combination of Lymphocyte populations of transplant eligible newly diagnosed Multiple Myeloma patients
    Santos, Allan
    Santos, Herbert
    Salvino, Marco
    Santos, Juliana
    Queiroz, Sarah
    Lucas, Larissa
    Almeida, Alessandro
    Santos, Mariane
    Leal, JOanna
    Arruda, Maria da Gloria
    Torres, Alex
    Crusoe, Edvan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S75 - S75
  • [2] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Santos, Juliana Andrade
    de Melo Santos, Herbert Henrique
    Santos, Allan de Souza
    Lucas, Larissa Ferreira
    Almeida, Alessandro de M.
    Chaves, Marcos
    Dutra, Daniela Dourado
    Hungria, Vania T. M.
    Salvino, Marco Aurelio
    Arruda, Maria da Gloria B.
    BLOOD, 2022, 140 : 7699 - 7700
  • [3] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
    Crusoe, Edvan
    Santos, Juliana
    Leal, JOanna
    Santos, Herbert
    Santos, Allan
    Almeida, Alessandro
    Santos, Mariane
    Lucas, Larissa
    Queiroz, Sarah
    Fonseca, Cleverson
    Adorno, Elisangela
    Vieira, Lucas
    Hungria, Vania
    Salvino, Marco
    Arruda, Maria da Gloria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130
  • [4] Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results
    Santos, Allan de Souza
    Santos, Herbert Henrique de Melo
    Salvino, Marco Aurelio
    Silva, Sarah Queiroz
    Lucas, Larissa Ferreira
    Almeida, Alessandro de M.
    Santos, Mariane Melo
    Santos, Juliana Andrade
    Hungria, Vania T. M.
    Arruda, Maria da Gloria B.
    Torres, Alex
    Crusoe, Edvan De Queiroz
    BLOOD, 2020, 136
  • [5] Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Salvino, Marco Aurelio
    Lucas, Larissa Ferreira
    Santos, Juliana Andrade
    Santos, Herbert Henrique de Melo
    Almeida, Alessandro de M.
    Santos, Allan de souza
    Chaves, Marcos
    Santos, Mariane Melo
    Silva, Sarah Queiroz
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Adorno, Elisangela
    Hungria, Vania
    Arruda, Maria da Gloria B.
    BLOOD, 2021, 138
  • [6] Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients
    Crusoe, Edvan de Queiroz
    Santos, Juliana
    Santos, Allan
    Santos, Mariane Melo
    Salvino, Marco Aurelio
    Adorno, Elisangela
    Moura, Alessandro
    Fonseca, Cleverson Alves
    Queiroz, Sarah
    Bomfim, Maria da Gloria
    Nicanor, Jamile
    Santos, Herbert Henrique
    Hungria, Vania
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E145 - E146
  • [7] Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients
    Crusoe, Edvan De Queiroz
    Salvino, Marco Aurelio
    Silva, Sarah Queiroz
    Santos, Herbert Henrique de Melo
    Santos, Allan de Souza
    Almeida, Alessandro de M.
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Lucas, Larissa Ferreira
    Leal, Joanna
    Santos, Mariane Melo
    Santos, Juliana Andrade
    Adorno, Elisangela
    Hungria, Vania T. M.
    Arruda, Maria da Gloria B.
    BLOOD, 2020, 136
  • [8] Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
    Crusoe, Edvan De Queiroz
    Higashi, Fabiana
    Martinez, Gracia
    Bittencourt, Rosane
    Pinto Neto, Jorge Vaz
    Sousa, Lais
    Santucci, Rodrigo
    Pessoa Magalhaes, Roberto Jose
    Colli, Gilberto
    Marques Nunes, Renata Ferreira
    Ribeiro, Glaciano
    Nicacio, Jandir
    Zanella, Karla Richter
    Kutner, Jose Mauro
    Magalhaes, Andre
    Leao, Danielle
    Hallack Neto, Abrahao Elias
    Braga, Walter
    Souza, Emanuella G.
    Guimaraes, Antonio Julio A. M.
    Durigon, Giovanna Steffenello
    Laks, Dani
    Maiolino, Angelo
    de Moraes Hungria, Vania Tietsche
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (02) : 118 - 124
  • [9] Daratumumab (DARA) plus Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
    Corre, Jill
    Vincent, Laure
    Moreau, Philippe
    Hebraud, Benjamin
    Hulin, Cyrille
    Bene, Marie
    Broijl, Annemiek
    Caillot, Denis
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Perrot, Aurore
    Zweegman, Sonja
    Hua, Winnie
    Krevvata, Maria
    Vanquickelberghe, Veronique
    Tuozzo, Alba
    Rowe, Melissa
    Carson, Robin
    Wuilleme, Soraya
    Avet-Loiseau, Herve
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S29 - S30
  • [10] Superiority of Triple Combination Bortezomib plus Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide plus Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients
    Crusoe, Edvan De Queiroz
    Higashi, Fabiana
    Martinez, Gracia
    Bittencourt, Rosane
    Maiolino, Angelo
    Sousa, Lais
    Nunes, Renata Ferreira Marques
    Ribeiro, Glaciano
    Nicacio, Jandir
    Zanella, Karla Richter
    Magalhaes, Andre
    Leao, Danielle
    Pinto Neto, Jorge Vaz
    Hallack Neto, Abrahao Elias
    Braga, Walter
    Souza, Emmanuella G.
    Guimaraes, Antonio Julio A. M.
    Durigon, Giovanna Steffenello
    Laks, Dani
    Kutner, Jose Mauro
    Colli, Gilberto
    Santucci, Rodrigo
    Magalhaes, Roberto Jose Pessoa
    Hungria, Vania T. M.
    BLOOD, 2017, 130
12345